Did You Know...
...that the Slinky toy was the result of a failed attempt by engineer Richard James to produce an antivibration device for ship instruments? His goal was to develop a spring that would instantaneously counterbalance the wave motion that rocks a ship at sea. Instead, he developed the Slinky.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8183340 | GLP-1 pegylated compounds The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1... | 05/22/2012 |
| 8110191 | Anti-IL-17 antibodies Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragm... | 02/07/2012 |
| 8066995 | Anti-myostatin antibodies Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for ... | 11/29/2011 |
| 8063188 | Anti-myostatin antibodies Monoclonal anti-myostatin antibodies that preferentially bind myostatin over GDF-11, have strong binding affinity to myostatin and are resistant to chemical degradation. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, ... | 11/22/2011 |
| 8057434 | Injection apparatus having a needle cassette for delivering a pharmaceutical liquid An apparatus for delivering a pharmaceutical liquid to a patient includes an outer casing; a needle cassette housed in the casing and containing a plurality of mutually parallel drug injection needles; a drug cartridge housed in the casing, containing a liquid and i... | 11/15/2011 |
| 7728109 | Antagonistic anti-hTNFSF13b human antibodies Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10−8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10âˆ... | 06/01/2010 |
| RE41133 | Glucagon-like peptide-1 crystals The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are ... | 02/16/2010 |
| 7598350 | Human anti-epidermal growth factor receptor antibody The present invention provides a fully human antibody that binds human EGFR with affinity comparable to or higher than IMC-C225, and that neutralizes activation of EGFR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivale... | 10/06/2009 |
| RE40876 | Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while m... | 08/18/2009 |
| 7557183 | Polyethylene glycol linked GLP-1 compounds The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGyla... | 07/07/2009 |
| 7498308 | Method of treating a subject suffering stroke comprising administering Glucagon-like peptide-1 analogs Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 com... | 03/03/2009 |
| 7452966 | GLP-1 analog fusion proteins The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bo... | 11/18/2008 |
| 7317089 | Antagonistic anti-hTNFSF13b human antibodies Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b(e.g., KD=10−8 M or less), a slow off rate for TNFSF13b dissociation (e.g., K | 01/08/2008 |
| 7271149 | GLP-1 fusion proteins The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other con... | 09/18/2007 |
| 7259233 | Chronic treatment regimen using glucagon-like insulinotropic peptides The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range. ... | 08/21/2007 |
| 7238663 | Pre-mixes of GLP-1 and basal insulin The present invention encompasses pre-mixed formulations comprising a GLP-1 polypeptide and a basal insulin. ... | 07/03/2007 |
| 7232879 | Glucagon-like insulinotropic peptides, compositions and methods The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the ... | 06/19/2007 |
| 7223728 | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while ... | 05/29/2007 |
| 7211557 | Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight. ... | 05/01/2007 |
| 7199217 | Amidated glucagon-like peptide-1 The present invention encompasses a GLP-1 analog and compositions and formulations thereof useful for the treatment of hyperglycemia and other various diseases and conditions in mammals. ... | 04/03/2007 |
| 7179788 | Biphasic mixtures of GLP-1 and insulin The present invention encompasses pharmaceutical formulations comprising a biphasic mixture which comprises a glucagon like peptide (GLP-1) compound in a solid phase and an insulin in a solution phase. ... | 02/20/2007 |
| 7144863 | GLP-1 formulations with protracted time action The present invention encompasses compositions wherein a GLP-1 compound is complexed with a basic polypeptide. The compositions provide a prolonged duration of action and can be administered by the pulmonary route. ... | 12/05/2006 |
| 7101843 | Glucagon-like peptide-1 analogs Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compound... | 09/05/2006 |
| 7084243 | Glucagon-like peptide-1 analogs Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating these GLP-1 compounds are also disclosed. ... | 08/01/2006 |
| 6747006 | Use of GLP-1 or analogs in treatment of myocardial infarction This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose. ... | 06/08/2004 |
| 6720407 | Method for administering insulinotropic peptides The claimed invention relates to a method of administering glucagon-like peptide-1 molecules by inhalation, a method for treating diabetes by administering glucagon-like peptide-1 molecules by inhalation, and a method for treating hyperglycemia by administering gluc... | 04/13/2004 |
